A meta-analysis of tirofiban hydrochloride (Aggrastat, Medicure) has been presented by primary investigator and lead author, Michael J Lipinski of the MedStar Heart and Vascular Institute, Washington, DC, presented the data at the 2016 Cardiovascular Research Technologies (CRT) conference.
The study was selected as a late-breaking iMPACT Trial at the CRT conference. The iMPACT session selects trials according to the perceived impact they may have on the field of interventional cardiology, with regards to innovations in quality of patient care.
The investigators pooled data from 41 randomised clinical trials to perform a network meta-analysis to directly and indirectly compare different glycoprotein IIb/IIIa inhibitor (GPI) strategies for percutaneous coronary intervention with a focus on the impact of high-dose bolus (HDB) tirofiban. A total of 38,645 patients were included in the analysis (2,654 randomised to HDB tirofiban, 6,752 to abciximab, 1,669 to eptifibatide, 16,500 to heparin, and 11,070 to bivalirudin). Results of the analysis found that HDB tirofiban had a significant reduction in all-cause mortality when compared with both heparin and eptifibatide (Integrilin, Merck & Co) (p<0.05). There was no significant difference among the GPI therapies for other outcomes including myocardial infarction, major adverse cardiac events and major bleeding.
This meta-analysis does not imply comparable efficacy, safety or product interchangeability. The data includes some patient populations which were outside of the approved populations for Aggrastat.